623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I

S2005 A phase II randomized study comparing ibrutinib and rituximab IR VS venetoclax and rituximab VR in previously untreated waldenstrom s macroglobulinemia WM lymphoplasmacytic lymphoma LPL

CaDAnCe 104 an ongoing open label phase 1b 2 master protocol study of Bruton tyrosine kinase degrader BGB 16673 in combination with other agents in patients with relapsed refractory B cell malignancies

A phase II study of acalabrutinib in combination with R CHOP for previously untreated transplant ineligible mantle cell lymphoma patients in Spain the SOUND MCL Study

Real world outcomes of sequencing bispecific antibodies BsAb in patients with relapsed refractory follicular lymphoma R R FL A multi center cohort study from cubic consortium

Funcional cure in advanced follicular lymphoma Real word experience from two academic centers from Argentina

Validation of novel prognostic models in symptomatic Waldenstroem s macroglobulinemia based on real world data

Assessment of minimal residual disease with droplet digital polymerase chain reaction for BRAF V600E mutation in patients with hairy cell leukemia treated with purine analogs

Efficacy of acalabrutinib in treatment naive Mantle Cell Lymphoma A systematic review and meta analysis

Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenstroem macroglobulinemia

FLIPI24 as a prognostic model in marginal zone lymphoma Results from an international multi cohort analysis

Preliminary efficacy and safety of TT 01488 a novel non covalent reversible BTK inhibitor in patients with relapsed refractory mantle cell lymphoma

Efficacy and safety of zanubrutinib containing regimens in patients with newly diagnosed Mantle Cell Lymphoma Interim results from a Phase II investigator initiated study

Indirect comparison of bendamustine rituximab and R CHOP with rituximab maintenance in first line treatment of elderly Mantle Cell Lymphoma Data from the enrich trial

Prognostic and therapeutic implications of the immune landscape in Mantle Cell Lymphoma

Optimal dose regimen of epcoritamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma analyses of pharmacokinetics and exposure response relationships of epcore FL 1 Phase 3 study

Phase 3 study inMIND of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma Clinical characteristics and outcomes of patients receiving second line treatment

Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high tumor burden follicular lymphoma

Real world efficacy and safety of orelabrutinib based regimens in the treatment of marginal zone lymphoma

Is ‘severe imcd IPL really severe

Efficacy and tolerability of bendamustine rituximab and acalabutinib in elderly treatment naïve Waldenstroem s macroglobulinemia

Real world treatment patterns and survival in splenic marginal zone lymphoma A national analysis in the rituximab era

Outcomes and prognostic factors in patients with follicular lymphoma treated with front line bendamustine and rituximab

Utility of 18F FDG PET CT for response assessment in marginal zone lymphomas Preliminary results of the IELSG44 international study

Trium study Exploring MRD guided triplet therapy with sonrotoclax zanubrutinib and CD20mab in Untreated Mantle Cell Lymphoma A prospective multicenter Phase II Study

Fixed duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated low tumor burden follicular lymphoma

Mosunetuzumab and lenalidomide combination therapy augments CD8 T cells with enhanced T cell dependent cytotoxicity against follicular lymphoma cells

Long term outcomes of patients with hairy cell leukemia treated with first line cladribine in British Columbia

Novel triplet combination of orelabrutinib lenalidomide and rituximab as frontlinetherapy for mantle cell lymphoma Final results of polaris multicenter phase II study

Hairy cell leukemia treatment strategies A real world multicenter experience

Phase 2 bellwave 003 cohort f Updated clinical outcomes of nemtabrutinib in participants with relapsed or refractory marginal zone lymphoma

Promising response rates and manageable safety with mosunetuzumab plus lenalidomide Mosun Len in patients with relapsed refractory R R follicular lymphoma FL US extension cohort from the Phase III CELESTIMO study

Two year update of ZUMA 2 Cohort 3 Brexucabtagene autoleucel Brexu cel in patients pts with relapsed refractory mantle cell lymphoma R R MCL who had not received prior Bruton tyrosine kinase inhibitor BTKi therapy

Comparison of real world survival outcomes and time toxicity of CAR T cell versus bispecific antibody therapies in relapsed refractory follicular lymphoma A multicenter cohort from 15 US academic institutions

Valemetostat monotherapy in patients with relapsed or refractory B cell lymphoma Final results of the Phase 2 valym study from the lysa

Real world treatment and safety outcomes of patients with Mantle Cell Lymphoma in the United States

Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenstroem macroglobulinemia